Back to Results
First PageMeta Content
Asthma / Leukotriene antagonists / Combination drugs / GlaxoSmithKline / Formoterol / Salmeterol / Fluticasone/salmeterol / Long-acting beta-adrenoceptor agonist / Metered-dose inhaler / Pulmonology / Respiratory therapy / Medicine


Oregon Health Resources Commission
Add to Reading List

Document Date: 2014-07-15 14:00:36


Open Document

File Size: 382,14 KB

Share Result on Facebook

Company

MEDLINE / Canadian Agency for Drugs / For pharmaceuticals / /

Country

United States / Canada / United Kingdom / /

Currency

CYP / USD / /

/

Event

FDA Phase / /

Facility

OHSU Center / University of North Carolina Evidence-based Practice Center / Oregon State University College of Pharmacy / National Institute / /

/

IndustryTerm

comparable delivery devices / administration devices / healthcare utilization / medical technology assessment / pharmaceutical subcommittee / pharmaceutical agents / pharmaceutical / pharmaceutical manufacturers / mcg/2ml solution / medical technology / pharmaceuticals / technology assessments / literature search / combination products / year new pharmaceuticals / healthcare providers / /

MedicalCondition

long-term asthma / COPD / inflammatory process / severe persistent asthma / reversible airway obstruction / persistent asthma / N/A No Asthma / acute asthma / uncontrolled asthma / mg/packet+ Granules Leukotriene receptor antagonists Approved Indication Asthma / obesity / inflammatory cells / wheezing / asthma / N/A No No No Asthma / airway obstruction / disease / N/A No No No No Asthma / mild persistent asthma / Clinical Overview Asthma / contraction of smooth muscles / Symbicort Turbuhaler®* DPI 100mcg/6mcg* 200mcg/6mcg* Asthma / No Asthma / coughing / mcg/blister / blister / chronic lung disease / N/A Asthma / exercise-induced bronchospasm / persistent asthma current recommendations / inflammation / /

MedicalTreatment

relaxation / /

Organization

Canadian Agency for Drugs and Technology / World Health Organization / North Carolina Evidence-based Practice Center / Food and Drug Administration / University of North Carolina / Center for Evidence-based Policy / office of Oregon Health Policy & Research / National Institute for Health and Clinical Excellence / Department of Human Services / Health Resources Commission / DMAP / Oregon State University College of Pharmacy / Oregon Legislature / FDA’s Center for Drug Evaluation and Research / Center for Biologics Evaluation and Research / Office for Oregon Health Policy & Research / Health Resources Commission Office for Oregon Health Policy & Research / /

Person

Kane / Justin Leonard / Tracy Klein / Ruth Medak / James MacKay / George Waldman / Asthma / Rich Clark / Manny Berman Dean Haxby / Katherine Merrill / Bill Origer / Kathy Ketchum / David Pass / Diane Lovell John Muench / Dan Kennedy / William Origer / Alison Little / /

/

Position

insurance industry representative / Assistant Director for Health / Vice Chair / physician / Staff Director / business representative / consumer representative / Governor / director / Nurse / chairperson / Chair / representative / Assistant / Controller / /

Product

fluticasone propionate / Accolate / flunisolide / AeroBid / Vanceril / Advair HFA / Symbicort / mometasone furoate / Serevent / Foradil / Asmanex Twisthaler / Brovana / Zyflo / Flovent Diskus / Beta / Flovent / Zyflo CR / Azmacort / Pulmicort / Singulair / This medication / triamcinolone acetonide / Xolair / Beta-2 / this / Chewable / Table1 / EIB.5 The / This agent / /

ProvinceOrState

Oregon / /

Technology

cell receptors / /

URL

www.oregon.gov/DAS/OHPPR/ORRX/HRC/evidence_based_reports.shtml / http /

SocialTag